Sunshine Biopharma, Inc.

Equities

SBFM

US8677816014

Pharmaceuticals

End-of-day quote Nasdaq 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
0.8074 USD -13.18% Intraday chart for Sunshine Biopharma, Inc. -54.25% -97.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product MT
Top Premarket Decliners MT
Sunshine Biopharma Shares Slump After Reverse Stock Split Announcement MT
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023. CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sunshine Biopharma, Inc. announced that it has received $5 million in funding CI
Sunshine Biopharma, Inc. announced that it expects to receive $0.01 million in funding CI
Sunshine Biopharma, Inc. Announces Executive Changes CI
Sunshine Biopharma, Inc. Announces Move Its Headquarters to New York City CI
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023. CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Jewish General Hospital Announces Termination of the Research Agreement with Sunshine Biopharma, Inc CI
Sunshine Biopharma Gets Extension to Comply With Nasdaq Minimum Bid Price Rule MT
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023. CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aegis Capital Initiates Sunshine Biopharma at Buy Rating With $2.60 MT
Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding CI
Wall Street Set to Open Higher; Import Prices Rebound More Than Expected MT
Sunshine Biopharma, Inc. announced that it expects to receive CAD 5 million in funding CI
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023. CI
Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sunshine Biopharma, Inc. Signs Exclusive Worldwide License with University of Arizona for PLpro-Based Covid-19 Treatment CI
Sector Update: Health Care Stocks Rise on Friday MT
Sunshine Biopharma Signs Research Deal with Canadian Hospital for Anticancer Compound; Shares Rise MT
Chart Sunshine Biopharma, Inc.
More charts
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has 27 additional generic prescription drugs. In addition, the Company is engaged in the development of various proprietary drugs, including Adva-27a, K1.1 mRNA and SBFM-PL4. Adva-27a is a small chemotherapy molecule targeting pancreatic cancer. The K1.1 mRNA is developed for liver cancer. SBFM-PL4 is an anti-coronavirus compound. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio consisting of 50 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.95 USD
Average target price
15 USD
Spread / Average Target
+1,478.95%
Consensus
  1. Stock Market
  2. Equities
  3. SBFM Stock
  4. News Sunshine Biopharma, Inc.
  5. Sector Update: Health Care Stocks Rising in Defensive Tuesday Trade